| Ytd | 54.01% | |
| 1y | 78.81% |
| Open | 2.05 | Prev Close | 2.08 | Low | 2.05 | High | 2.18 | Mkt Cap | 728.28M |
| Vol | 12.84M | Avg Vol | 11.37M | EPS | -0.77 | P/E | N/A | Forward P/E | -1.50 |
| Beta | 0.84 | Short Ratio | 11.46 | Inst. Own | 80.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.10 | 200-d Avg | 1.80 | 1yr Est | 9.04 |
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers f
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progr
Allogene Therapeutics said on Wednesday it has ended a key partnership for ​developing cell therapie
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the an
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, C
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day tra
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1
Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a
Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises
US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir
Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect A
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling pote
Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market P
Argus Research analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Mar
Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Out
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and rai
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options
Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an u
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de
U.S. stock futures lower, Dow futures down 300 points. Worthington Steel Inc (NYSE: WS) shares fall